The uneven landscape of Swiss travel behavior: evidence of mobility inequality from the national microcensus. [PDF]
NPJ Sustain Mobil TranspHudecek MFC, Kammer JK, Moser C.
europepmc +1 more source
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Molecular Oncology, EarlyView.Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source
Understanding socioeconomic disparities in travel behavior during the COVID-19 pandemic. [PDF]
J Reg Sci, 2021 Brough R, Freedman M, Phillips DC.
europepmc +1 more source
Molecular Oncology, EarlyView.Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena +15 more
wiley +1 more source
JUE Insight: The Geography of Travel Behavior in the Early Phase of the COVID-19 Pandemic. [PDF]
J Urban Econ, 2022 Brinkman J, Mangum K.
europepmc +1 more source
Molecular Oncology, EarlyView.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
Socio-economic disparities in activity-travel behavior adaptation during the COVID-19 pandemic in North Carolina. [PDF]
Transp Policy (Oxf), 2022 Wang J, Kaza N, McDonald NC, Khanal K.
europepmc +1 more source
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Traveling Before, During, and After the Pandemic: Impact of the COVID-19 Pandemic on the Travel Behavior and Travel Medicine Practice. [PDF]
CureusFigueiredo I +7 more
europepmc +1 more source
A double jeopardy: COVID-19 impacts on the travel behavior and community living of people with disabilities. [PDF]
Transp Res Part A Policy Pract, 2022 Park K +8 more
europepmc +1 more source